发布求助
文献互助 智能选刊 最新文献

European journal of rheumatology and inflammation最新文献

筛选
英文 中文
Comparative evaluation of tenoxicam and piroxicam in the treatment of humeroscapular periarthritis. 替诺昔康与吡罗西康治疗肩胛骨周炎的比较评价。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
G Gotter
{"title":"Comparative evaluation of tenoxicam and piroxicam in the treatment of humeroscapular periarthritis.","authors":"G Gotter","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"95-7"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14455768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of non-steroidal anti-inflammatory drugs in sports injuries. 非甾体抗炎药在运动损伤中的作用。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
R D'Ambrosia
{"title":"The role of non-steroidal anti-inflammatory drugs in sports injuries.","authors":"R D'Ambrosia","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The running population in the United States is estimated to be more than 60 million, and two out of every three of these runners will seek medical attention because of injuries. The cause of lower extremity injuries is the impulsive impact that occurs on foot strike. At 800 foot strikes per mile, a 150-pound runner will be subjected to forces of 120 tons per foot per mile. The use of the non-steroidal anti-inflammatory drugs (NSAIDs) in runners has become widespread. This is especially true in the case of marathon runners who use NSAIDs like piroxicam to relieve their overuse pains so they can continue to run with injuries, although this use is not advocated. NSAIDs do, however, play a role in treating many running injuries and can help the runner return to his chosen sport.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"54-9"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14245139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Piroxicam: new dosage forms. 吡罗昔康:新剂型。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
E Norris, M Guttadauria
{"title":"Piroxicam: new dosage forms.","authors":"E Norris,&nbsp;M Guttadauria","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Patient acceptance of medications often depends upon individual and cultural preferences for particular dosage forms. A variety of dosage forms also provides the patient and the physician with greater convenience and flexibility. Thus, multiple formulations increase the clinical utility of a drug. In addition to the capsule, dosage forms of piroxicam now available or in an advanced stage of clinical development include a suppository, dispersible tablet, topical gel, and parenteral formulation. (Ed.: The parenteral and topical formulations were launched after the symposium was held, and are now available). The piroxicam suppository offers an alternative to the oral route of administration. Pharmacokinetic studies demonstrate that the 20-mg suppository is bioequivalent to the 20-mg capsule, and clinical studies have shown that it is equal to the capsule in efficacy and toleration. Piroxicam is the only non-steroidal anti-inflammatory drug (NSAID) that is available as a dispersible tablet. This dosage form is also well tolerated by patients and equally effective as the capsule. Intramuscular administration of piroxicam is in development. All these dosage forms offer the convenience of once-a day administration. Piroxicam topical gel (0.5%) has been demonstrated to have anti-inflammatory activity in several animal models. In double-blind clinical trials involving patients with osteoarthritis of the knee, the topical gel was found to be significantly more effective than placebo and well tolerated.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"94-104"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14433460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and tolerability of tenoxicam--an overview. 替诺昔康的疗效和耐受性综述。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
T L Vischer
{"title":"Efficacy and tolerability of tenoxicam--an overview.","authors":"T L Vischer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>One-hundred and thirty-three clinical studies have been conducted with tenoxicam in patients with rheumatoid arthritis, osteoarthrosis, extra-articular rheumatism, ankylosing spondylitis and acute gouty arthritis. Its efficacy has been demonstrated in double-blind comparative studies against placebo, and dose-finding studies have found the optimal dose to be 20 mg. Most trials comparing tenoxicam with another NSAID have used piroxicam, an earlier oxicam derivative which also has a long half-life. In general, efficacy was similar in both drugs with a trend in favour of tenoxicam. The tolerability of tenoxicam has also been studied in detail. In short-term studies 11% of patients receiving 20 mg tenoxicam and 18% on 40 mg tenoxicam experienced side-effects (p less than 0.01), as did 20% treated with 20 mg piroxicam (p less than 0.01 against 20 mg tenoxicam). In long-term studies clinical tolerability of 20 mg tenoxicam was found to be superior to that of 20 mg piroxicam. The types of side-effects encountered were mainly gastrointestinal disturbances, followed in frequency by skin rashes. However, all side-effects were generally mild and reversible. The efficacy of tenoxicam is clearly established and its tolerability is acceptable with a 20 mg dose. Tenoxicam thus seems a promising drug and a useful addition to the therapeutic armamentarium.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"51-7"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14455760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis. 替诺昔康(Ro 12-0068)与吡罗西康在强直性脊柱炎患者中的双盲平行临床试验
European journal of rheumatology and inflammation Pub Date : 1987-01-01
G Astorga
{"title":"Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis.","authors":"G Astorga","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"70-3"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14455762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term treatment with tenoxicam in rheumatoid arthritis. 替诺昔康长期治疗类风湿关节炎。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
J J Orozco-Alcalá, E F Barrera-Tenorio
{"title":"Long-term treatment with tenoxicam in rheumatoid arthritis.","authors":"J J Orozco-Alcalá,&nbsp;E F Barrera-Tenorio","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"118-21"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14456021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of tenoxicam in patients with acute gouty arthritis. 替诺昔康在急性痛风性关节炎患者中的应用。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
E F Valdés
{"title":"Use of tenoxicam in patients with acute gouty arthritis.","authors":"E F Valdés","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"133-6"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14456025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview on the pharmacokinetics of tenoxicam. 替诺昔康的药代动力学研究综述。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
T W Guentert, R C Heintz, R Joly
{"title":"Overview on the pharmacokinetics of tenoxicam.","authors":"T W Guentert,&nbsp;R C Heintz,&nbsp;R Joly","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tenoxicam, a new non-steroidal anti-inflammatory drug (NSAID) with an oxicam structure, is entirely ionised at physiological pH, has minimal lipophilic properties, high plasma protein binding, does not accumulate in fatty tissue and skin and thus has a small volume of distribution. Tenoxicam is rapidly and completely absorbed after oral administration. It is entirely metabolised via oxidation and conjugation pathways before elimination. The extraction ratio in the liver is small resulting in a long elimination half-life with a mean of 72 hours. Since no unchanged drug is found in the bile the low half-life cannot be explained by enterohepatic recirculation of parent compound. The low elimination rate of tenoxicam allows for a once-daily dosage (20 mg) regimen. Following multiple dosing during the first two weeks of therapy tenoxicam reaches steady-state levels within 10-20% of predicted values. Several pharmacokinetic factors help make tenoxicam therapy safe and straightforward: it is completely absorbed when taken orally even with meals or antacids, it penetrates easily into synovial fluid, and is excreted as inactive metabolites. Furthermore, drug disposition is not influenced by age, sex or rheumatic disease and unexpected accumulation is not observed.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"15-25"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14456026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Milestones in anti-inflammatory therapy. 抗炎治疗的里程碑。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
E C Huskisson
{"title":"Milestones in anti-inflammatory therapy.","authors":"E C Huskisson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The anti-inflammatory era opened with aspirin, which for decades was the first-line treatment for rheumatoid arthritis. Striking advances have occurred in recent years with the introduction of propionic acid derivatives like ibuprofen and once-a-day drugs like piroxicam. The class now includes a range of drugs with properties suited to the range of clinical indications presented by rheumatic disorders. Anti-inflammatory drugs are now and will continue to be the mainstay of symptomatic therapy for arthritis.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"3-5"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14621298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low back pain. 腰痛。
European journal of rheumatology and inflammation Pub Date : 1987-01-01
L Simon
{"title":"Low back pain.","authors":"L Simon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Low back pain is a frequent medical complaint that is often the result of a conflict between a compressed or degenerated disc and the inflamed nerve root. The discoradicular conflict is best treated with dual modality therapy: mechanical treatment to relieve disc compression and anti-inflammatory treatment for the congested root. Almost all cases of acute low back pain can be treated with conservative therapy, including the use of non-steroidal anti-inflammatory drugs (NSAIDs), and surgery should be used only as a last resort. Results of a study comparing oral administration of piroxicam with indomethacin and diclofenac for reduction of spontaneous low back pain indicated that the three drugs are nearly identical in efficacy. In other investigations, intramuscular piroxicam (one injection of 40 mg/d for two days, then 20 mg/d) performed favorably in terms of pain relief and tolerance as compared with higher doses of intramuscular ketoprofen and diclofenac administered in two daily doses.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"65-7"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14091293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信